Research Finds that Stereotaxis Robotic Technology Provides Significant Advantages in Treatment of Ventricular Tachycardia Compared to Manual Techniques

ST. LOUIS, Aug. 14, 2017 -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced the results of an independent meta-analysis of studies reporting the comparative safety, efficacy, and efficiency of its Niobe^® remote magnetic navigation system versus manual navigation in ablation for ventricular tachycardia (VT). The analysis, published in the Journal of Interventional Cardiac Electrophysiology, represents the largest systematic review of VT findings with the Niobe system, comprising data from 779 patients treated at multiple prominent global hospitals.

The results of the analysis demonstrated that the Niobe system is associated with a 39% lower risk of VT recurrence (p = 0.003), higher acute procedural success during VT ablation (p = 0.0004) and a 65% reduction in risk of complications during VT ablation (p = 0.006). Additionally, procedure time was significantly shorter by an average of 9.8 min with the Niobe system (p = 0.04) and fluoroscopy time was significantly reduced by an average of 10.4 min (p < 0.00001). The publication abstract can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/28624892.

Senior author Dr. Dhanunjaya Lakkireddy, Professor of Cardiovascular Medicine at the University of Kansas Medical Center, commented, “The Niobe system has overcome many of the limitations inherent with manual ablation techniques in complex procedures, yet studies to date of its impact on VT ablation have been limited in size and consistency. This was an opportunity to pool data for a significant statistical analysis comparing robotic to manual approaches, the results of which verified the Niobe system’s advantages in recurrence rate, procedure time, and complications. We believe the performance benefits lie in the improved reach and precision provided by robotics as well as the continuous consistent tissue contact generated by a magnetic ablation catheter.”  

Stereotaxis is currently conducting a prospective, multi-center, randomized control clinical study to demonstrate superiority of robotic cardiac ablation compared to manual approaches in VT patients.     

About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.    

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Stereotaxis Contacts:                                                            
David Fischel
Chairman and Acting Chief Executive Officer

Martin C. Stammer                                                                             
Chief Financial Officer

[email protected]